Erratum: Development of a molecule-recognized promoter DNA sequence for inhibition of HER2 expression

Correction to: The Journal of Antibiotics (2009) 62, 339–341; doi:10.1038/ja.2009.35

The authors of the above noted an error in the publication of this paper (AOP and in this issue) in the legend of Figure 1 and y axis of Figure 2. The corrected Figures 1 and 2 are shown below.

Figure 1

Designed pyrrole–imidazole polyamide targeting HER2 promoter region. (a) Targeting HER2 promoter region. Bold lines are targeting sequences. Open circles: Py (N-methylpyrrole); black circles: Im (N-methylimidazole); ß: beta-alanine; Ac: Acetyl; Dp: N, N-dimethylaminopropylamine; ): γ-aminobutyric. (b) Chemical structure of PI polyamide-HER2.

Figure 2

Effects of PI polyamide-HER2 on cell growth and mRNA expression in MDA-MB-231 cell. (a) Effects of PI polyamide-HER2 on the growth of COLO205, HT29, MCF-7 and MDA-MB-231 cells in a proliferation assay. Test compounds were dissolved in 50% DMSO at appropriate concentrations and treated for 72 h. Black squares: colo205 (IC₅₀>100 μM); black circles: HT29 (IC₅₀<100 μM); open circles: MCF-7 (IC₅₀>100 μM); open squares: MDA-MB-231 (IC₅₀=30 μM). (b) PI polyamide-HER2 treatment decreased HER2 expression in MDA-MB-231 cells. The cell had been treated with different concentrations of PI polyamide-HER2 for 48 h, and HER2 mRNA expression was determined by quantitative real-time PCR experiments. The HER2 mRNA expression levels were expressed as a relative percentage to the control value. Data are expressed as the mean±s.d. (n=3 for each group). The statistical significance of differences between control and experimental groups was determined by using a two-group two-tailed Student's t-test; ^**P<0.01 was taken as the level of statistical significance.